HC Wainwright & Co. Maintains Buy on Cabaletta Bio, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Cabaletta Bio (NASDAQ:CABA) and raises the price target from $15 to $17.

August 11, 2023 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the raised price target could potentially boost Cabaletta Bio's stock in the short term.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the 'Buy' rating maintained by HC Wainwright & Co. and the raised price target from $15 to $17 indicates a positive outlook for Cabaletta Bio, which could potentially lead to an increase in its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100